Radionetics Oncology Initiates Phase 1 Radiopharmaceutical Program for Adrenocortical Carcinoma
Radionetics Oncology has initiated a Phase 1 clinical trial for 68Ga-R8760, a pioneering radioligand imaging agent designed to detect adrenocortical carcinoma. The study, R8760-101 (NCT05999292), focuses on assessing the agent’s safety and dosimetry. Dr….
Continue Reading
